European Society for Medical Oncology Preceptorship on Metastatic Bladder and Kidney Cancer Lugano 2023

40 $

+ Include: 37 videos + 38 pdfs, size: 1.83 GB

+ Target Audience: oncologist

Description

+ Include: 37 videos + 38 pdfs, size: 1.83 GB

+ Target Audience: oncologist

+ Sample video: contact me for sample video

+ Information:

Start date: 27 Mar 2023
End date: 28 Mar 2023
Location: Lugano, Switzerland

Learning objectives

  • To learn about fundamentals of molecular pathology and diagnosis as contributing factors to heterogeneity in bladder and kidney cancer
  • To understand essentials in the assessment and multidisciplinary treatment of bladder and kidney cancer
  • To learn about advances in treatment and novel targets in bladder and kidney cancer

 

 

+ Topics:

ESMO-Preceptorship-on-Metastatic-Bladder-and-Kidney-Cancer-2023-Lugano-Programme.pdf
Session 1 Approaches to Upper Tract UC.mp4
Session 1 Approaches to Upper Tract UC.pdf
Session 1 Localized and Systemic Standard Treatments in Non-Muscle-Invasive Bladder Cancer Localized Treatments.mp4
Session 1 Localized and Systemic Standard Treatments in Non-Muscle-Invasive Bladder Cancer Localized Treatments.pdf
Session 1 Localized and Systemic Standard Treatments in Non-Muscle-Invasive Bladder Cancer Surgery.mp4
Session 1 Localized and Systemic Standard Treatments in Non-Muscle-Invasive Bladder Cancer Surgery.pdf
Session 1 New Treatments and Approaches to NMIBC.mp4
Session 1 New Treatments and Approaches to NMIBC.pdf
Session 2 Debate Adjuvant Chemotherapy or Immune Therapy for MIBC Adjuvant Chemotherapy.mp4
Session 2 Debate Adjuvant Chemotherapy or Immune Therapy for MIBC Adjuvant Chemotherapy.pdf
Session 2 Debate Adjuvant Chemotherapy or Immune Therapy for MIBC Immune Therapy.mp4
Session 2 Debate Adjuvant Chemotherapy or Immune Therapy for MIBC Immune Therapy.pdf
Session 2 Established and Novel Neoadjuvant Treatments for MIBC.mp4
Session 2 Established and Novel Neoadjuvant Treatments for MIBC.pdf
Session 2 First Line Treatment in Advanced Bladder Cancer.mp4
Session 2 First Line Treatment in Advanced Bladder Cancer.pdf
Session 2 Participants Clinical Case Discussion A Perioperative High Grade Lymphoepithelioma-Like Bladder Cancer Treated With Neoadjuvant Anti-PD1+CT A Clinical Case.mp4
Session 2 Participants Clinical Case Discussion A Perioperative High Grade Lymphoepithelioma-Like Bladder Cancer Treated With Neoadjuvant Anti-PD1+CT A Clinical Case.pdf
Session 2 Participants Clinical Case Discussion Complication of Neo-Adjuvant Non-Standard Immunotherapy What Can We Learn.mp4
Session 2 Participants Clinical Case Discussion Complication of Neo-Adjuvant Non-Standard Immunotherapy What Can We Learn.pdf
Session 2 Participants Clinical Case Discussion Cutaneous Toxicities Management of Enfortumab Vedotin in Metastatic Urothelial Carcinoma Two Clinical Cases.mp4
Session 2 Participants Clinical Case Discussion Cutaneous Toxicities Management of Enfortumab Vedotin in Metastatic Urothelial Carcinoma Two Clinical Cases.pdf
Session 2 Sequencing Therapy in Advanced Bladder Cancer.mp4
Session 2 Sequencing Therapy in Advanced Bladder Cancer.pdf
Session 3 Is There a Role for Nephrectomy in Advanced disease.mp4
Session 3 Is There a Role for Nephrectomy in Advanced disease.pdf
Session 3 Neoadjuvant and Adjuvant Treatment in RCC.mp4
Session 3 Neoadjuvant and Adjuvant Treatment in RCC.pdf
Session 3 Participants Clinical Case Discussion Belzutifan with Lenvatinib in VHL Associated Renal Cell Cancer.mp4
Session 3 Participants Clinical Case Discussion Belzutifan with Lenvatinib in VHL Associated Renal Cell Cancer.pdf
Session 3 Participants Clinical Case Discussion Characterising Spontaneous Regression in Metastatic ccRCC.mp4
Session 3 Participants Clinical Case Discussion Characterising Spontaneous Regression in Metastatic ccRCC.pdf
Session 3 Participants Clinical Case Discussion Papillary Renal Cell Carcinoma What is The Best Therapeutic Sequencing.mp4
Session 3 Participants Clinical Case Discussion Papillary Renal Cell Carcinoma What is The Best Therapeutic Sequencing.pdf
Session 3 Participants Clinical Case Discussion Sarcoid-Like Reaction During Adjuvant Therapy with Immune Checkpoint Inhibitors for Papillary Renal Carcinoma.mp4
Session 3 Participants Clinical Case Discussion Sarcoid-Like Reaction During Adjuvant Therapy with Immune Checkpoint Inhibitors for Papillary Renal Carcinoma.pdf
Session 3 Surgery and Other Techniques for Primary Tumour.mp4
Session 3 Surgery and Other Techniques for Primary Tumour.pdf
Session 3 The Role of Metastasectomy and SBRT in RCC.mp4
Session 3 The Role of Metastasectomy and SBRT in RCC.pdf
Session 4 Biology and Treatment of Non-Clear RCC.mp4
Session 4 Biology and Treatment of Non-Clear RCC.pdf
Session 4 Debate Immune Combinations or VEGF PD1 Inhibition as 1st Line Therapy for Advanced Clear Cell RCC Immune Combinations.mp4
Session 4 Debate Immune Combinations or VEGF PD1 Inhibition as 1st Line Therapy for Advanced Clear Cell RCC Immune Combinations.pdf
Session 4 Debate Immune Combinations or VEGF PD1 Inhibition as 1st Line Therapy for Advanced Clear Cell RCC VEGF PD1 Inhibition.mp4
Session 4 Debate Immune Combinations or VEGF PD1 Inhibition as 1st Line Therapy for Advanced Clear Cell RCC VEGF PD1 Inhibition.pdf
Session 4 Second Line and Beyond.mp4
Session 4 Second Line and Beyond.pdf
Session 5 Biomarkers beyond PD-L1 in Bladder Cancer.mp4
Session 5 Biomarkers beyond PD-L1 in Bladder Cancer.pdf
Session 5 Circulating Biomarkers in Bladder and Kidneys Cancer.mp4
Session 5 Circulating Biomarkers in Bladder and Kidneys Cancer.pdf
Session 5 New Drugs in Bladder Cancer Beyond ADCs.mp4
Session 5 New Drugs in Bladder Cancer Beyond ADCs.pdf
Session 5 New Drugs in RCC Targeted, Immune and Cellular Therapies.mp4
Session 5 New Drugs in RCC Targeted, Immune and Cellular Therapies.pdf
Session 5 Personalized Therapy in RCC Fact or Fiction.mp4
Session 5 Personalized Therapy in RCC Fact or Fiction.pdf
Session 6 ADCs Present and Future in Bladder Cancer.mp4
Session 6 ADCs Present and Future in Bladder Cancer.pdf
Session 6 Can we Stop Targeted Therapy, Immune or ADC Therapy.mp4
Session 6 Can we Stop Targeted Therapy, Immune or ADC Therapy.pdf
Session 6 Optimising CTLA-4 in Renal and Bladder Cancer.mp4
Session 6 Optimising CTLA-4 in Renal and Bladder Cancer.pdf
Session 6 Participants Clinical Case Discussion Nausea and Ataxia in a Patient with Metastatic Clear Cell Renal Carcinoma Not as Clear as it Seems.mp4
Session 6 Participants Clinical Case Discussion Nausea and Ataxia in a Patient with Metastatic Clear Cell Renal Carcinoma Not as Clear as it Seems.pdf
Session 6 Participants Clinical Case Discussion Nephrectomy and Metastasectomy Post First Line Combination Immunotherapy for Metastatic Clear Cell RCC.mp4
Session 6 Participants Clinical Case Discussion Nephrectomy and Metastasectomy Post First Line Combination Immunotherapy for Metastatic Clear Cell RCC.pdf
Session 6 Participants Clinical Case Discussion The Role of Cytoreductive Nephrectomy in the Era of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma.mp4
Session 6 Participants Clinical Case Discussion The Role of Cytoreductive Nephrectomy in the Era of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma.pdf
Session 6 Treatment after Progression on Adjuvant Therapy in Renal and Bladder Cancer.mp4
Session 6 Treatment after Progression on Adjuvant Therapy in Renal and Bladder Cancer.pdf
Welcome from ESMO – Objectives and Scientific Introduction.mp4
Welcome from ESMO – Objectives and Scientific Introduction.pdf

Reviews

There are no reviews yet.

Be the first to review “European Society for Medical Oncology Preceptorship on Metastatic Bladder and Kidney Cancer Lugano 2023”

Your email address will not be published. Required fields are marked *